Biglycan and uses thereof in stabilizing dystrophin associated protein complexes
CA 2392046 C · Owner: Mercado, Mary Lynn · Inventors: Mckechnie, Beth; Fallon, Justin; Bowe, Mark
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides compositions and methods for treating preventing, and , diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g. to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy Becker's Muscular , Dystrophy, neuromuscular disorders and neurological disorders.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 17, 2000 and granted July 12, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 17, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 17, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.